Physidia Announces Leadership Transition: Julien Dolivet Appointed as New CEO
Saint-Barthélemy-d’Anjou, France
Physidia, the European leader in home haemodialysis, today announces a key leadership change with the appointment of Julien Dolivet as new Chief Executive Officer, taking over from Didier Candelot.
Didier Candelot joined the company in October 2019 and has been instrumental in establishing Physidia as a leader in the development, production, and commercialization of innovative mobile home haemodialysis solutions, with a strong focus on operational excellence. He will continue to contribute to the company’s success, joining the company’s board as a Board Observer.
“It has been a privilege to lead Physidia over the last 4 years. I am proud of what we achieved as a team over that period, consolidating Physidia’s leading position in Europe, driving operational excellence and significantly improving the financial profile of the company. Physidia is now more robust and ready to embark into an accelerated growth phase, led by my successor, Julien Dolivet, and leveraging the resources our new financial partner, Columna Capital. I look forward to contributing further to the project through my new role as a Board Observer,” said Didier Candelot.
Julien Dolivet brings extensive experience in the home care sector to Physidia. His background includes significant leadership roles such as VP of Global Marketing at Hollister Inc., a global leader in ostomy and continence care, CEO of FSK, a French homecare company and Managing Director France & Benelux at Linde Healthcare. With his homecare experience, coupled with his vision for the renal sector, Julien Dolivet is uniquely positioned to lead Physidia in its mission to enhance patients’ quality of life through innovative home haemodialysis solutions.
“I am thrilled to join Physidia at such an exciting time for the company and for the sector where the shift towards home is accelerating globally. Physidia is fundamentally transforming the home haemodialysis landscape, building on its 10-year track record in the market with exceptional results. My focus will be to leverage my homecare experience to deliver on our mission, expand our reach and continue to offer exceptional patient-focused home dialysis solutions,” said Julien Dolivet.
This leadership transition marks the beginning of a new chapter in Physidia’s history as it continues to play a key role in the development of the home haemodialysis market, with a particular focus on improving the patients’ quality of life. The change follows the significant investment made by Columna Capital, with the objective to accelerate its international growth strategy while continuing to invest significantly in R&D.
